Cardiometabolic Comorbidities in Cancer Survivors

Zullig, Leah L.; Sung, Anthony D.; Khouri, Michel G.; Jazowski, Shelley A.; Shah, Nishant; Sitlinger, Andrea; Blalock, Dan V.; Whitney, Colette; Kikuchi, Robin; Bosworth, Hayden B.; Crowley, Matthew J; Goldstein, Kenneth M.; Klem, Igor; Oeffinger, Kevin C.; Dent, Susan

doi:10.1016/j.jaccao.2022.03.005

Cited by 37 publications

(25 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the American Cancer Society (ACS) stated the importance of nutrition after cancer diagnosis and treatment to avoid adverse health outcomes such as cancer recurrence, cardiovascular disease (CVD), and mortality in the ACS Nutrition and Physical Activity Guideline for Cancer Survivors [1]. However, limited information is available on the association between dietary sodium intake and impaired fasting glucose (IFG), a common metabolic disorder that could potentially progress to diabetes, leading to adverse health outcomes in cancer survivors [2][3][4][5][6][7][8][9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Association of dietary sodium intake with impaired fasting glucose in adult cancer survivors: A population-based cross-sectional study

Kim

Jun

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

Background Dietary sodium intake is a crucial lifestyle factor that should be assessed in adult cancer survivors due to their increased risk of adverse health outcomes compared to the general population. However, its with impaired fasting glucose (IFG) in adult cancer survivors remains unclear. This study aimed to investigate the association of dietary sodium intake categorized by the American Heart Association (AHA) recommendation with IFG in the community-dwelling adult cancer survivors. Methods A total of 1,052 adult cancer survivors without diabetes were identified from the sixth and seventh Korea National Health and Nutrition Examination Survey (KNHANES), 2013–2018. Data on dietary sodium intake was categorized as <1,500 mg/day, 1,500–2,999 mg/day, 2,300–3,999 mg/day, and ≥4,000 mg/day according to the AHA recommendation. A multiple logistic regression model adjusted for demographic, lifestyle, and health status was used to compute odds ratios (OR) and 95% confidence intervals (95% CI) for IFG according to dietary sodium intake categories. Results After adjusting for confounding variables identified in the KNHANES, the adjusted OR among the adult cancer survivors who consumed 1,500–2,999 mg/day, 2,300–3,999 mg/day, and ≥4,000 mg/day of dietary sodium were 1.16 (95% CI: 0.25–5.27), 1.93 (95% CI: 0.40–9.37), and 2.67 (95% CI: 0.59–12.18), respectively, as compared to those who consumed <1,500 mg/day (P value for trend = 0.036). Conclusion Among community-dwelling adult cancer survivors, high dietary sodium intake was marginally associated with increased odds of IFG. Well-designed cohort studies or randomized clinical trials are needed to establish more epidemiologic evidence on this association in adult cancer survivors.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of dietary sodium intake with impaired fasting glucose in adult cancer survivors: A population-based cross-sectional study

Kim

Jun

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The management of various CVRF in patients receiving active cancer therapy can be challenging and requires close monitoring. Additional hurdles are imposed by reduced adherence to oral antihypertensives, antidiabetics and statins, following cancer diagnosis 47. Careful shared decision-making and personalised patient support are critically needed.…”

Section: Cardiovascular Risk Factors Approach In Patients With Breast...mentioning

confidence: 99%

Common origins and shared opportunities for breast cancer and cardiovascular disease prevention

Henry

Vaidean

Rege

et al. 2023

Heart

View full text Add to dashboard Cite

“…Hypertension is a prevalent modifiable CVRF, affecting approximately 32% of adults aged 40 to 59 years in the United States [7]. Although ICIs have not been associated with increased risk of developing hypertension [8], it is probable that a significant proportion of cancer patients treated with ICIs will have preexisting or independently develop hypertension during follow up [9]. Hypertension during cancer survivorship has been shown to be associated with subsequent cardiovascular morbidity and mortality [10].…”

Section: Introductionmentioning

confidence: 99%

Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

et al. 2023

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.

show abstract

Cardiometabolic Comorbidities in Cancer Survivors

Cited by 37 publications

References 169 publications

Association of dietary sodium intake with impaired fasting glucose in adult cancer survivors: A population-based cross-sectional study

Association of dietary sodium intake with impaired fasting glucose in adult cancer survivors: A population-based cross-sectional study

Common origins and shared opportunities for breast cancer and cardiovascular disease prevention

Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

Contact Info

Product

Resources

About